How Are the New Lupus Nephritis Guidelines Impacting Treatment?
Perspective by renowned nephrologist Dr. Brad Rovin Recognized as National Kidney Month, March is the ideal time to learn more...
voclosporin
Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023
The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...
Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis
September 21, 2022
Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults...
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021
The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...
Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting
November 9, 2021
Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College...
Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback
April 20, 2021
At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an...
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
NEW YORK, NY. January...
Promising New Lupus Treatments Highlighted ACR Annual Meeting
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR...
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways
Results from...
Results of Two Voclosporin Trials Presented at Key Medical Meeting
October 22, 2020
Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored...
LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA
NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA...
Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020
One of the largest meetings for rheumatologists went virtual this year to enable scientists from around...